Table 3.
Characteristics of splenectomized ITP patients
| Patients | Sex | Age, y | Lowest platelet count during the 3 mo before splenectomy | Previous treatments | Last treatment received | Time since the last therapy, wk | Disease duration before splenectomy, mo | Interval between RTX and splenectomy, mo | Response to splenectomy |
|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 16.8 | 31 | Steroids; dapsone; IVIg | IVIg | 2 | 4.4 | CR | |
| 2 | F | 21.3 | 9 | Steroids; dapsone | Steroids | 0 | 30.4 | CR | |
| 3 | F | 55.2 | 21 | Steroids; dapsone; IVIg | IVIg | 1.5 | 13.2 | CR | |
| 4 | M | 18.9 | 28 | Steroids; dapsone; IVIg | IVIg | 1 | 16.0 | CR | |
| 5 | F | 49.6 | 5 | Steroids; dapsone; IVIg | IVIg | 1 | 206.4 | CR | |
| 6 | F | 23.5 | 20 | Steroids; dapsone; IVIg | IVIg | 1 | 8.1 | NR | |
| 7 | F | 27.5 | 20 | Steroids; IVIg | IVIg | 1.5 | 17.5 | CR | |
| 8 | M | 22.5 | 24 | Steroids; dapsone; IVIg | IVIg | 1 | 22.1 | CR | |
| 9 | F | 42.7 | 20 | Steroids; dapsone; IVIg; RTX | IVIg | 1 | 16.5 | 6.9 | CR |
| 10 | F | 78.7 | 6 | Steroids; dapsone; IVIg; RTX | IVIg | 3 | 3.7 | 2.3 | NR |
| 11 | F | 79.5 | 13 | Steroids; IVIg; RTX | IVIg | 1 | 7.9 | 7.5 | NR |
| 12 | F | 87.7 | 6 | Steroids; dapsone; IVIg; RTX | IVIg | 1 | 9.2 | 8.4 | CR |
| 13 | M | 74.0 | 4 | Steroids; dapsone; IVIg; RTX | IVIg | 1 | 121.0 | 2.3 | NR |
| 14 | M | 75.8 | 18 | Steroids; dapsone; IVIg; RTX | IVIg | 1 | 87.3 | 5.6 | NR |
| 15 | F | 58.5 | 25 | Dapsone; IVIg; RTX | IVIg | 1 | 37.6 | 14.7 | CR |
| 16 | F | 71.0 | 18 | Steroids; dapsone; vincristine; IVIg; RTX | IVIg | 1 | 12.4 | 5.8 | CR |
| 17 | F | 31.1 | 15 | Steroids; IVIg; RTX | Steroids | 0 | 22.2 | 9.6 | CR |
| 18 | M | 80.1 | 29 | Steroids; IVIg; RTX; romiplostim | Romiplostim | 1 | 12.2 | 9.0 | CR |
CR indicates complete response; and NR, no response.